Target intelligence / Profile preview

Bungarus neurotoxin (BTX)

Target
BTX
Molecular classification
Three-finger toxin, Phospholipase A2, Snake venom neurotoxin
01

Overview

Bungarus neurotoxins are a group of highly potent proteinaceous toxins found in the venom of kraits, specifically Bungarus multicinctus and Bungarus candidus. These toxins are primarily classified into alpha-bungarotoxins, which are post-synaptic three-finger toxins, and beta-bungarotoxins, which are pre-synaptic phospholipase A2 enzymes [1, 2]. Alpha-bungarotoxins bind with high affinity and near-irreversibility to nicotinic acetylcholine receptors at the neuromuscular junction, leading to a blockade of neuromuscular transmission [1, 3]. Beta-bungarotoxins act by depleting synaptic vesicles and damaging motor nerve terminals, further contributing to paralysis [2, 4]. Clinically, these toxins cause severe envenomation characterized by progressive muscle weakness and respiratory failure, which is the leading cause of death in krait bite victims [3, 5]. Therapeutic intervention relies on the administration of specific antivenoms that target and neutralize these toxins in the bloodstream [3]. Beyond their role in pathology, these neurotoxins, particularly alpha-bungarotoxin, are essential pharmacological tools used to study the structure and function of acetylcholine receptors [1].

Other names
BungarotoxinKrait neurotoxinAlpha-bungarotoxinBeta-bungarotoxinGamma-bungarotoxinKappa-bungarotoxinMany-banded krait neurotoxinMalayan krait neurotoxin
02

Mechanism of action

Antivenoms contain specific antibodies or antibody fragments that bind to the neurotoxins, neutralizing their ability to interact with physiological targets such as nicotinic acetylcholine receptors or presynaptic membranes, thereby preventing or reversing paralysis [3, 5].

03

Biological functions

Nicotinic acetylcholine receptor antagonismInhibition of presynaptic neurotransmitter releaseNeuromuscular blockadePhospholipase A2 activity
04

Disease associations

Snakebite envenomationRespiratory failureParalysis
05

Safety considerations

Rapid onset of respiratory paralysisAnaphylactic reaction to antivenomSerum sicknessIrreversible binding of post-synaptic toxins
06

Interacting drugs

Bungarus multicinctus antivenom

3 more in the full profile.

07

Biomarkers

Serum venom antigen levelsClinical neurotoxicity signs (ptosis, ophthalmoplegia)Respiratory minute volume

Beyond the preview

Go deeper on Bungarus neurotoxin (BTX).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bungarus neurotoxin (BTX).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call